| |
Partial Spearman correlations for variables with <30% outside the LOD
|
% <LOD for one or both samples
|
Rate of sample 2 <LOD where sample 1 <LOD
|
|---|
|
n
|
Partial correlation, 95% CI
|
p value
|
|---|
|
Cytokines
|
|
IL-1A
|
26
|
.33 (−.09–.64)
|
.11
|
16
|
1/5 (20%)
|
|
IL-IRA
| | | |
87
|
21/25 (84%)
|
|
IL-1B
| | | |
87
|
23/27 (85%)
|
|
IL-2
| | | |
84
|
20/23 (87%)
|
|
sIL-2RA
| | | |
65
|
15/17 (88%)
|
|
IL-3
| | | |
52
|
15/15 (100%)
|
|
IL-4
| | | |
97
|
29/29 (100%)
|
|
IL-5
|
28
|
.85 (.68–.93)
|
<.0001
|
10
|
1/3 (33%)
|
|
IL-6
| | | |
94
|
28/29 (97%)
|
|
IL-7
| | | |
71
|
19/19 (100%)
|
|
IL-9
|
31
|
.82 (.63–.91)
|
<.0001
|
0
|
na
|
|
IL-10
| | | |
35
|
8/11 (73%)
|
|
IL-12p40
| | | |
61
|
13/19 (68%)
|
|
IL-12p70
| | | |
94
|
24/25 (96%)
|
|
IL-13
| | | |
100
|
30/31 (97%)
|
|
IL-15
|
31
|
.80 (.61–.90)
|
<.0001
|
0
|
na
|
|
IL-17
| | | |
94
|
27/28 (96%)
|
|
IFNα2
|
30
|
.74 (.50–.87)
|
<.0001
|
3
|
0/1 (0%)
|
|
IFNγ
| | | |
68
|
16/18 (89%)
|
|
TNFα
|
31
|
.62 (.32–.80)
|
.004
|
0
|
na
|
|
TNFβ
| | | |
65
|
12/16 (75%)
|
|
TGFα
|
31
|
.84 (.67–.92)
|
<.0001
|
0
|
na
|
|
Growth factors
|
|
EGF
| | | |
100
|
31/31 (100%)
|
|
G-CSF
|
31
|
.53 (.19–.75)
|
.003
|
0
|
na
|
|
GM-CSF
|
31
|
.72 (.48–.86)
|
<.0001
|
0
|
na
|
|
VEGF
| | | |
97
|
26/29 (90%)
|
|
FGF-2
| | | |
74
|
17/21 (81%)
|
|
FLT-3L
|
31
|
.82 (.64–.91)
|
<.0001
|
0
|
na
|
|
sCD40L
|
27
|
.63 (.30–.82)
|
.0008
|
13
|
1/4 (25%)
|
|
Chemokines
|
|
CCL2 (MCP-1)
|
31
|
.64 (.35–.81)
|
.0002
|
0
|
na
|
|
CCL3 (MIP-1α)
| | | |
58
|
9/13 (69%)
|
|
CCL4 (MIP-1β)
| | | |
48
|
12/12 (100%)
|
|
CCL7 (MCP-3)
| | | |
71
|
12/19 (63%)
|
|
CCL11 (EOTAXIN)
| | | |
97
|
26/30 (87%)
|
|
CCL22 (MDC)
| | | |
32
|
5/10 (50%)
|
|
CXCL1 (GRO)
|
29
|
.53 (.18–.75)
|
.004
|
6
|
0/2 (0%)
|
|
CXCL8 (IL-8)
|
31
|
.51 (.17–.74)
|
.004
|
0
|
na
|
|
CXCL10 (IP-10)
|
31
|
.50 (.16–.73)
|
.01
|
0
|
na
|
|
CX3CL1 (FRACTALKINE)
|
31
|
.42 (.06–.68)
|
.02
|
0
|
na
|
- Note: <LOD = below the lower limit of detection; na = not applicable. No restrictions were placed on time-to-follow-up for inclusion in these analyses. Mean age for sample 1 was 3.51 ± 0.95 years; mean time-to-follow-up was 2.44 ± 0.68 years. Spearman’s correlation was calculated where at least 70% of the sample had detectable values at both visits. Listwise deletion was used in correlation analyses; thus, individuals with out-of-range values were excluded. Age at sample 1 and time-to-follow-up were partialled out in correlation analyses. Variables with high rates of values outside the range of detection were analyzed as categorical; because of the small sample size and complete or quasi-complete separation, it was not possible to calculate reliable odds ratio estimates for these variables
